# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kashmiri et al.

Application No. 09/830,748

Filed: April 30, 2001

For: VARIANTS OF HUMANIZED

**ANTI-CARCINOMA MAB CC49** 

Examiner: Not yet assigned

Date: July 2, 2002

BOX PCT/SEQUENCE COMMISSIONER FOR PATENTS P.O. BOX 2327 ARLINGTON, VA 22202 Art Unit: Not Yet Assigned

#### CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on July 2, 2002 as First Class Mail in an envelope addressed to: BOX PCT/SEQUENCE, COMMISSIONER FOR PATENTS, P.O. BOX 2327,

ARLINGTON, VIRGINIA, 22202.

Susan Alpert Siegel, Ph/I Agent for Applicant

#### RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

In response to the Notification of Defective Response, dated June 7, 2002, for which a one-month period for reply was set, making the response due on or before July 7, 2002, please amend the above-identified application as follows:

Please enter in the file the enclosed computer-readable form (submitted on 3.5 inch diskette) and paper copy of the Sequence Listing, replacing all existing computer-readable forms and paper copies of the Sequence Listing previously submitted.

# REMARKS

In compliance with 37 C.F.R. §1.821(f), the undersigned declares that the nucleotide and amino acid sequences presented in the computer-readable form of the "Sequence Listing" submitted herein are the same as the sequences contained in the paper copy of the "Sequence Listing" also submitted herein. No new matter has been added by this amendment.

# **CONCLUSION**

If any minor matters remain to be discussed prior to examination, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

SAS:dag 07/02/02 126042 PATENT Attorne Application Number 4239-61725
Application Number 09/830.748

# 533 Rec'd PCT/PTO 08 JUL 2002

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kashmiri et al.

Application No. 09/830,748

Kiled: April 30, 2001

VARIANTS OF HUMANIZED ANTI-CARCINOMA MAB CC49

aminer: Not yet assigned

Date: July 2, 2002

Art Unit: Not yet assigned

#### **CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on July 2, 2002 as First Class Mail in an envelope addressed to: BOX PCT/SEQUENCE, COMMISSIONER FOR PATENTS, P.O. BOX 2327, ARLINGTON, VIRGINIA, 22202.

Susan Alpert Siegel Agent for Applicant

BOX PCT/SEQUENCE COMMISSIONER FOR PATENTS P.O. BOX 2327 ARLINGTON, VA 22202

Enclosed is a Response to Notification of Defective Response for the above application. Applicants believe no fee is currently due.

Response to Notification of Defective Response, including a Declaration under 37 C.F.R. §1.821(f).

Replacement Sequence Listing in computer-readable form and paper copy (12 pages).

Copy of Notification of Defective Response.

Please charge any additional fees that may be required, or credit any overpayment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446



### UNITED STATES PATENT AND TRADEMARK OFFICE

1239-61725NIH/SAS

Commissioner for Patents, Box PC United States Patent and Tradamark Office Washington, D.C. 2023

ATTY, DOCKET NO. FIRST NAMED APPLICANT U.S. APPLICATION NUMBER NO. 11613.32USWO Sved V S Kashmiri 09/830,748 INTERNATIONAL APPLICATION NO. DOCKETED FOR: PCT/US99/25552 I.A. FILING DATE PRIORITY DATE Melissa Jean Pytel COMPUTER 10/29/1999 10/31/1998 Merchant & Gould P O Box 2903 CARD Minneapolis, MN 55402-0903 BOOK **CONFIRMATION NO. 2031** DRAWER **371 FORMALITIES LETTER** IN. SVE OC000000008250626\* Date Mailed: 06/07/208 NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- o U.S. Basic National Fee
- o Priority Document
- o Biochemical Sequence Listing
- o Copy of IPE Report
- o Copy of references cited in ISR
- Copy of the International Application
- o Copy of the International Search Report
- o Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items MUST be furnished within the period set forth below:

- o The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
  - APPLICANT MUST PROVIDE:





- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.824(g), 1.825(b) or 1.825(d).
- o For guestions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - □ For Rules Interpretation, call (703) 308-4216
  - □ To Purchase Patentin Software, call (703) 306-2600
  - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

#### BARBARA A CAMPBELL

Telephone: (703) 305-3631

#### PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
09/830,748	PCT/US99/25552	11613.32USWO

FORM PCT/DO/EO/916 (371 Formalities Notice)